AIGEN Sciences
AIGEN Sciences is an AI-driven drug discovery company that accelerates the identification of new drugs, aiming to find a drug candidate within 6 months. They leverage specialized biomedical Large Language Models (LLMs) trained on scientific papers and drug databases, enabling them to sift through millions of papers, identify drug targets, and engineer molecules efficiently. Their AI Platform offers capabilities such as target discovery, literature search and summarization, hypothesis generation, multi-omics data analysis, patent and FTO search, molecular docking, simulation, and ADMET prediction. The company emphasizes a human-in-the-loop approach, fostering collaboration between researchers and AI systems to amplify decision-making and reduce R&D timelines by over 70%. AIGEN Sciences is also recognized for developing BioBERT, a highly cited biomedical LLM, and Meerkat 7B, a compact LLM capable of passing the USMLE.
AIGEN Sciences
AIGEN Sciences is an AI-driven drug discovery company that accelerates the identification of new drugs, aiming to find a drug candidate within 6 months. They leverage specialized biomedical Large Language Models (LLMs) trained on scientific papers and drug databases, enabling them to sift through millions of papers, identify drug targets, and engineer molecules efficiently. Their AI Platform offers capabilities such as target discovery, literature search and summarization, hypothesis generation, multi-omics data analysis, patent and FTO search, molecular docking, simulation, and ADMET prediction. The company emphasizes a human-in-the-loop approach, fostering collaboration between researchers and AI systems to amplify decision-making and reduce R&D timelines by over 70%. AIGEN Sciences is also recognized for developing BioBERT, a highly cited biomedical LLM, and Meerkat 7B, a compact LLM capable of passing the USMLE.